**Table S3. Percentage of patients who report meeting or exceeding the MCID ≥2.5 for the physical and mental component scores (PCS and MCS) of the SF-36**

|  |  |
| --- | --- |
|  | **% of patients achieving MCID ≥2.5** |
|  | **Physical Component Score** | **Mental Component Score** |
| **Week** | Placebo(N=488) | Baricitinib (N=487) | Adalimumab (N=330) | Placebo (N=488) | Baricitinib (N=487) | Adalimumab (N=330) |
| 4 | 53 | 72\*\*\* | 67\*\*\* | 41 | 43 | 43 |
| 8 | 56 | 77\*\*\*++ | 68\*\*\* | 40 | 45 | 42 |
| 12 | 55 | 78\*\*\*++ | 70\*\*\* | 47 | 46 | 47 |
| 16 | 55 | 77\*\*\*+++ | 66\*\* | 41 | 45 | 47 |
| 20 | 59 | 78\*\*\*++ | 69\*\*\* | 43 | 44 | 45 |
| 24 | 60 | 79\*\*\*+ | 72\*\*\* | 47 | 50\*\* | 47 |
| 28 |  | 78+++ | 72 |  | 46 | 49 |
| 32 |  | 76+++ | 72 |  | 46++ | 44 |
| 40 |  | 75+++ | 72 |  | 45+++ | 45 |
| 52 |  | 72+++ | 69 |  | 46+++ | 44 |

\*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.001 versus placebo; +p≤0.05, ++p≤0.01, +++p≤0.001 versus adalimumab